FindTrial
Sign In

PEG-interferon alfa-2a

DRUG11 trials

Sponsors

M.D. Anderson Cancer Center, National Institutes of Health Clinical Center (CC), University of California, San Diego, Bristol-Myers Squibb, University of Southern California

Conditions

Breast CancerHepatitis B, ChronicHepatitis CHepatitis C InfectionHepatitis C VirusHepatitis C, ChronicMetastatic CancerNeoplasm of Uncertain Malignant Potential

Phase 1

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
CompletedNCT00253474
National Institutes of Health Clinical Center (CC)Neoplasm of Uncertain Malignant Potential, Unspecified Childhood Solid Tumor, Protocol Specific
Start: 2005-09-30End: 2011-01-31Target: 36Updated: 2012-03-29
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
NCT00423397
University of California, San DiegoNon-melanomatous Skin Cancer
Start: 2006-09-30Target: 16Updated: 2013-12-19
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
CompletedNCT02174172
Hoffmann-La RocheSolid Cancers
Start: 2014-08-18End: 2019-11-25Updated: 2020-05-12
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
CompletedNCT03272009
Enyo PharmaHepatitis B, Chronic
Start: 2017-09-21End: 2018-07-30Updated: 2018-08-21

Phase 2

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
TerminatedNCT00227656
M.D. Anderson Cancer CenterBreast Cancer, Metastatic Cancer
Start: 2005-09-30End: 2006-11-30Updated: 2012-12-11
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
CompletedNCT01125189
Bristol-Myers SquibbHepatitis C Virus
Start: 2010-07-31End: 2012-08-31Updated: 2015-10-23
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
TerminatedNCT01153919
University of Southern CaliforniaHepatitis C Infection, Thrombocytopenia
Start: 2010-06-30End: 2018-07-14Updated: 2017-04-11
Ph IIA Study (SOC +/- NS5B)
CompletedNCT01193361
Bristol-Myers SquibbHepatitis C Virus
Start: 2010-10-31End: 2012-11-30Updated: 2015-10-09

Phase 3

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
CompletedNCT01389323
Bristol-Myers SquibbHepatitis C
Start: 2011-09-30End: 2014-01-31Updated: 2015-10-12
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
CompletedNCT01544920
Merck Sharp & Dohme LLCHepatitis C, Chronic
Start: 2012-05-30End: 2015-05-19Updated: 2018-09-11
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
CompletedNCT01573351
Bristol-Myers SquibbHepatitis C Virus
Start: 2012-05-31End: 2013-12-31Updated: 2015-10-09

Related Papers

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
2015-02-1931 citations
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
Gut2014-07-30118 citations